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Abstract 
Hepatocellular carcinoma (HCC) is a highly complex cancer, resistant to commonly 
used treatments and new therapeutic agents are urgently needed. A total of thirty-two 
thieno[3,2-b]pyridine derivatives of two series: methyl 3-amino-6-
(hetero)arylthieno[3,2-b]pyridine-2-carboxylates (1a-1t) and methyl 3-amino-6-
[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates (2a-2n), previously 
prepared by some of us, were evaluated as new potential anti-HCC agents by studying 
their in vitro cell growth inhibition on human HepG2 cells and hepatotoxicity using a 
porcine liver primary cell culture (PLP1). The presence of amino groups linked to a 
benzene moiety emerges as the key element for the anti-HCC activity. The methyl 3-
amino-6-[(3-aminophenyl)ethynyl]thieno[3,2-b]pyridine-2-carboxylate (2f) is the 
most potent compound presenting GI50 values on HepG2 cells of 1.2 µM compared to 
2.9 µM of the positive control ellipticine, with no observed hepatotoxicity (PLP1 
GI50>125 µM against 3.3 µM of ellipticine). Moreover this compound changes the cell 
cycle profile of the HepG2 cells, causing a decrease in the % of cells in the S phase 
and a cell cycle arrest in the G2/M phase. QSAR studies were also performed and the 
correlations obtained using molecular and 1D descriptors revealed the importance of 
the presence of amino groups and hydrogen bond donors for anti-HCC activity, and 
hydrogen bond acceptors for hepatotoxicity. The best correlations were obtained with 
3D descriptors belonging to different subcategories for anti-HCC activity and 
hepatotoxicity, respectively. These results point to different molecular mechanisms of 
action of the compounds in anti-HCC activity and hepatotoxicity. This work presents 
some promising thieno[3,2-b]pyridine derivatives for potential use in the therapy of 
HCC. These compounds can also be used as scaffolds for further synthesis of more 
potent analogues.  
 
Keywords: Thieno[3,2-b]pyridines; Anti-hepatocellular carcinoma activity; 
Hepatotoxicity; Cell cycle, QSAR studies 
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1. Introduction  
Hepatocellular carcinoma (HCC) is a major health problem with more than 660,000 new 
cases per year worldwide [1]. HCC is a rapid fatal disease with a life expectancy of about 6 
months from the time of diagnostics, and has the third highest mortality rate among all 
cancers [2]. The highest prevalence for HCC occurs in Asia and sub-Saharan Africa 
countries, mainly due to endemic hepatitis B and C and food contaminated by Aflatoxin B. 
In Western countries and Japan, the incidence has increased dramatically over the past 
decades, mainly due to the rise in hepatitis C virus (HCV) infection, cirrhosis related to 
type II diabetes, and non-alcoholic steatohepatitis [3,4].  
Despite the available surgical treatment options, the majority of HCC patients have 
inoperable disease with very poor prognosis [5,6]. Also, the frequent presence of 
recurrence, metastasis or the development of new primary tumors, results in survival rates 
of 25–50% 5-year after surgery [7]. Alternative or palliative treatment options are very 
limited due to resistance to conventional chemotherapy and radiotherapy [8]. Because of 
the lack of survival benefits of treatment with conventional drugs, there is a need for more 
therapies with pharmacological agents, to help improve the prognosis of patients with 
HCC.  
Sorafenib, a multikinase inhibitor, is the only approved drug for HCC treatment, although it 
is effective in a wide range of tumor models [9]. In vivo and in vitro studies have shown 
that sorafenib inhibits tumor growth and disrupts tumor microvasculature through 
antiproliferative, antiangiogenic, and/or pro-apoptotic effects. Sorafenib has shown 
antitumor activity in phase II/III trials involving patients with advanced renal cell 
carcinoma and hepatocellular carcinoma. The multiple molecular targets of sorafenib, the 
serine/threonine kinase Raf and VEGFR (the proangiogenic vascular endothelial growth 
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factor receptor) and PDGFR (platelet-derived growth factor receptor) tyrosine kinases, may 
explain its broad preclinical and clinical activity [10]. The relative success of Sorafenib, 
which was found to prolong about 3 months the average survival time of patients with 
advanced HCC, suggest that the small-molecule targeted chemotherapy can be a promising 
strategy to combat this cancer [11]. In fact several compounds are already under preclinical 
investigation, and accumulating evidence suggests that combination therapy targeting 
different pathways will potentiate anti-cancer effects and will become the future therapeutic 
approach [8]. 
HepG2, Hep3B, Huh7.5 and SK-Hep1 are commonly used human HCC cell lines [12]. 
Nevertheless, HepG2 is the most widely used cell line and generally regarded as a good 
HCC model [13-15]. In this study, thirty two methyl 3-aminothieno[3,2-b]pyridine-2-
carboxylate derivatives, synthesized in our group [16-18], were evaluated as potential new 
anti-HCC agents by studying their in vitro cell growth inhibition activity using HepG2 
cells. Furthermore, an initial assessment of possible compound toxicity was performed by 
studying their in vitro cell growth inhibition activity in a porcine liver primary cell culture 
(PLP1). The cell culture methodology to establish PLP1 as a good initial model for in vitro 
hepatotoxicity is described. The cell profile of the most promising compound (more active 
and less toxic) was analysed. QSAR (Quantitative Structure-Activity Relationships) studies 
were also performed for the anti-HCC activity and hepatotoxicity in order to provide some 
insights on the molecular interactions of the compounds studied with proteins involved in 
signaling pathways. 
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2. Results and Discussion 
 
2.1. Establishment of a porcine liver primary cell culture for hepatotoxicity studies  
In order to perform a preliminary study of in vitro toxicity in normal liver cells a porcine 
liver primary cell culture (PLP1) was established. These primary cells (also referred as 
normal early passage cells) have undergone very few population doublings and are 
therefore more representative of the main functional component of the tissue from which 
they are derived in comparison to continuous (tumor or artificially immortalized) cell lines  
[19].  
This assay is very important since mammalian hepatocytes still represent an obligatory step 
in the evaluation of toxic compounds that lead to the production of various metabolites, 
which are the ultimate cause of toxicity. We used porcine liver as an in vitro cytotoxicity 
model because it is known, in terms of cellular and physiological functioning, to be very 
similar to human [20]. The use of non-tumor liver cells is even more important in this 
work, as we are studying the effect of the methyl 3-aminothieno[3,2-b]pyridine-2-
carboxylates derivatives in liver cancer (hepatocellular carcinoma). Although a human 
primary cell culture or even fresh isolated human hepatocytes would be preferred, there are 
still a number of ethical concerns to consider when using fresh human tissue for cell lines 
establishment. The use of porcine primary cells allows for a preliminary toxicity screening 
of the compounds in normal liver cells. This screening narrows the number of compounds 
that will then be further screened, using in vitro and/or in vivo human liver for 
hepatotoxicity. 
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Although the use of the PLP1 culture will not give us a definite answer, no hepatotoxicity 
(no in vitro screening will do that) it is still a cheaper, faster and ethically defensible, to 
perform preliminary hepatotoxicity studies. 
 
2.2. Anti-hepatocellular carcinoma (HCC) activity using HepG2 cells and hepatotoxicity: 
SAR analysis 
 
In this study, a total of thirty-two methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylates 
derivatives, belonging to two different series: the methyl 3-amino-6-(hetero)arylthieno[3,2-
b]pyridine-2-carboxylates derivatives (1a-1t) [17] and the methyl 3-amino-6-
[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates derivatives (2a-2n) [18], were 
evaluated for the in vitro anti-HCC (Hepatocellular carcinoma) activity and hepatotoxicity. 
Anti-HCC activity was studied by performing in vitro HepG2 cell growth inhibition assays. 
The HepG2 is a HCC derived cell line commonly used as a good model for in vitro anti-
HCC studies. To investigate the possible hepatotoxicity of the thirty-two compounds, an in 
vitro cell growth inhibition assay was performed using PLP1. The GI50 values for both anti-
HCC and hepatotoxicity studies are presented in tables 1 and 2. 
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Table 1- Growth inhibition activity (GI50) of compounds 1a-t and ellipticine, against 
HepG2 and PLP1 cells.  
N
S
NH2
CO2Me
R1 1
2
3
4
5
6
7  
Compound R1 HepG2 GI50 (µM) 
PLP1 
GI50 (µM) 
1a 4-MeOC6H4 >125 >125 
1b 3,5-diMeOC6H3 124.6 ± 3.7 25.0 ± 4.1 
1c 4-MeCOC6H4 >125 >125 
1d 2-NH2C6H4 21.7 ± 2.0 >125 
1e 4-CNC6H4 >125 96.7 ± 9.8 
1f 4-CF3C6H4 >125 >125 
1g Pyrid-3-yl >125 >125 
1h 6-MeOPyrid-3-yl- >125 >125 
1i 6-FPyrid-3-yl- >125 47.0 ± 12.5 
1j 2,4-diMeOPyrimid-5-yl- 23.8  ± 4.0 4.4  ± 0.8 
1l Fur-3-yl >125 >125 
1m 1-Me-1H-pyrazol-4-yl >125 >125 
1n Thien-3-yl >125 25.2 ± 5.4 
1o Naphth-2-yl >125 101.7 ± 1.3 
1p Quinol-6-yl >125 14.1 ± 2.1 
1q Quinol-3-yl >125 32.5 ± 5.8 
1r Isoquinol-4-yl >125 25.4 ± 1.9 
1s 1-methyl-1H-indol-5-yl 117.2 ± 2.3 105.7 ± 3.9 
1t 2,2’-Bithien-5-yl 70.6 ± 8.5 105.7 ± 12.3 
Ellipticine ___________ 2.9 ± 0.3 3.3 ± 0.7 
Results are given in concentrations that were able to cause 50% of cell growth inhibition (GI50) after a 
continuous exposure of 72 h and show means ± SEM of three-independent experiments. 
Ellipticine was used as a control. 
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 Table 2- Growth inhibition activity (GI50) of the compounds 2a-n and ellipticine, against 
HepG2 and PLP1 cells.  
N
S
NH2
CO2Me
1
2
3
4
5
6
7
R1  
Compound R1 HepG2 GI50 (µM) 
PLP1 
GI50 (µM) 
2a Ph >125 95.7 ± 10.0 
2b 2-MeOC6H4 >125 121.2 ± 19.2 
2c 3-MeOC6H4 >125 >125 
2d 4-MeOC6H4 >125 76.5 ± 9.7 
2e 2-NH2C6H4 >125 >125 
2f 3-NH2C6H4 1.2 ± 0.2 >125 
2g 4-NH2C6H4 25.9  ± 1.9 >125 
2h 2-FC6H4 >125 >125 
2i 4-FC6H4 >125 >125 
2j 4-(Me)2NC6H4 67.6 ± 9.8 >125 
2l Thien-3-yl 30.0 ± 2.0 30.7 ± 5.6 
2m Pyrid-2-yl 75.7 ± 10.7 56.9 ± 12.0 
2n Pyrid-3-yl >125 >125 
Ellipticine ___________ 2.9 ± 0.3 3.3 ± 0.7 
Results are given in concentrations that were able to cause 50% of cell growth inhibition  
(GI50) after a continuous exposure of 72 h and show means ± SEM of three-independent  
experiments. Ellipticine was used as a control. 
 
To better rationalize the results, the five most potent compounds for anti-HCC activity are 
presented on Figure 1: 1d and 1j from the methyl 3-amino-6-(hetero)arylthieno[3,2-
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b]pyridine-2-carboxylates series (Table 1); 2f, 2g and 2l from the methyl 3-amino-6-
[(heteroaryl)ethynyl]thieno[3,2-b]pyridine-2-carboxylates series (Table 2).  
 
 
Figure 1. Compounds with best cell growth inhibition activity against HepG2 cells, 
showing different hepatotoxicity in PLP1. 
 
The dose-response curves used to calculate GI50 values for the 5 compounds (and the 
positive control ellipticine) are presented for both anti-HCC activity (Figure 2a) and 
hepatotoxicity (Figure 2b).  
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Figure 2. Dose–response analysis of cell growth inhibition activity for compounds 1j, 1d, 
2l, 2f, 2g and ellipticine (positive control) against: (a) HepG2 cells and (b) PLP1 cells. 
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Analyzing the five compounds for anti-HCC activity it is observed that compound 2f, with 
the substituent 3-aminophenylethynyl, is the most potent compound presenting the lowest 
GI50 value (1.2 µM compared to 2.9 µM value of the positive control ellipticine), while 1d, 
1j, 2g and 2l present GI50 values from 20 to 30 µM. Analyzing the same compounds for 
potential hepatotoxicity (using the PLP1 cell culture) it is observed that: compounds 1d, 2f 
and 2g present low to none PLP1 cell growth inhibition activity, up to the concentration 
tested, while compounds 1j and 2l present high PLP1 cell growth inhibition activity, with 
1j being the most hepatotoxic of this study (GI50 = 4.4 µM). Taken together, these results 
clearly indicate that the presence of a 2-aminophenyl substituent in 1d and a 3 or 4-
aminophenylethynyl substituents in 2f and 2g, linked to position 6 of the methyl 3-
aminothieno[3,2-b]pyridine-2-carboxylate scaffold, is the key factor for anti-HCC activity 
and low hepatotoxicity (Fig. 1). Compounds 1j with a 2,4-dimethoxypyrimid-5-yl and 2l 
with a thien-2-yl, respectively, linked to position 6 of the thieno[3,2-b]pyridine scaffold, 
although showing anti-HCC activity are not viable options as anti-HCC agents, due to their 
hepatotoxicity. Furthermore, the position of the amino group seems to be important, as 
compound 2f, with the amino group in the meta position of the phenylethynyl substituent, 
is the most potent anti-HCC compound (GI50 = 1.2 µM), while the less potent compounds 
1d and 2g (GI50 values 21.7 and 25.9 µM, respectively) have amino groups in the ortho and 
para positions on the phenyl and phenylethynyl substituents. A careful analysis of figure 
2(b) shows that, although it was not possible to calculate GI50 values for compounds 1d and 
2g, due to low hepatotoxicity, they still presented a small percentage of PLP1 cell growth 
inhibition at the highest concentration evaluated of 125 µM. This is even more interesting 
when it was observed that the most potent anti-HCC compound 2f presents no 
hepatotoxicity, even at the highest concentrations evaluated. 
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In general we observe that, the presence of several substituents linked to position 6 of the 
methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate moiety contributed to hepatotoxicity 
including: a dimethoxyphenyl  in 1b and a methoxyphenylethynyl  in 2d, a 6-fluoro-3-
pyrid-3-yl in 1i and a pyrid-2-ylethynyl in 2m, a thien-3-yl in 1n and a thien-2-ylethynyl in 
2l and notably quinolines (1p, 1q, 1r). These compounds are not suitable scaffolds for 
pursuing synthesis of compounds with more efficient anti-HCC activity and low 
hepatotoxicity. 
A recent study performed by Zeng et al. [13] showed a number of thieno[2,3-b]pyridine 
derivatives with strong cell growth inhibition activity against HepG2 cells. Remarkably 
some of the compounds studied presented HCC-specific anticancer activity. Although using 
a different thienopyridine scaffold (thieno[2,3-b]pyridine instead of our thieno[3,2-
b]pyridine), this is exciting evidence that corroborate the anti-HCC potential of the 
compounds presented in our study. However, the compounds presented in that study were 
not studied for hepatotoxicity and, based on the SAR analysis performed above, it is 
predicted that some of the compounds will probably present some degree of hepatotoxicity. 
Taken together, our findings show that the most potent compounds presented in this work, 
above all 2f, are good candidates for chemotherapy against HCC, with minimal potential 
hepatotoxicity effects.  
Therefore we further analyzed the cell cycle profile of exponentially growing HepG2 cells 
treated for 72h with compound 2f. The results are presented in Figure 3. Since the cells 
were growing exponentially during the entire course of the experiment, the blank cells 
(treated with complete medium only) and control cells (treated with DMSO) present a 
higher % of cells in S phase than that found in cells reaching confluence (data not shown). 
Results from cells treated with compound 2f show that this compound causes a significant 
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decrease in the % of cells in the S phase and a significant cell cycle arrest (increase in the 
% of cells) in the G2/M phase of the cell cycle. 
 
 
Figure 3 Effect of the compound 2f in HepG2 cell cycle profile.  
Blank cells (treated with medium only) and Control cells (treated with the vehicle, DMSO) were also 
included. Results are the mean±SEM of three independent experiments. *Represents p<0.05. 
 
The cell cycle analysis allowed us to verify that following treatment of cells with 
compound 2f, there was only a slight (not statistically significant) increase in the sub-G1 
peak (which is suggestive of apoptosis) indicating that the mechanism of action of this 
compound does not probably involve apoptosis. An attempt was made to study apoptosis 
but, unfortunately, this compound presents fluorescence, interfering with the assays that we 
have currently implemented in our laboratory (Annexin V/PI labelling by flow cytometry 
and TUNEL).  
 
2.3. QSAR studies for anti-HCC and hepatotoxicity activities 
The anti-HCC activity and hepatotoxicity of the methyl 3-amino-thieno[3,2-b]pyridine-2-
carboxylates derivatives was studied and a SAR analysis was performed. Still, this analysis 
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was purely based on chemical intuitions on the substituent effects of series of compounds. 
To better understand the studied biological activities in a quantitative manner, and to 
provide insights on the mechanism of action, we set out to perform QSAR studies. 
Compounds with no calculated GI50 values, due to lack of biological activity up to the 125 
µM DMSO solubility limit, were not used for this (were left out of this) analysis, as they 
would distort this quantitative analysis. In the end QSAR studies were performed with: ten 
compounds with anti-HCC activity (1b, 1d, 1j, 1s, 1t, 2f, 2g, 2j, 2l and 2m) and 16 with 
hepatotoxic activity (1b, 1e, 1i, 1j, 1n, 1o, 1p, 1q, 1r, 1s, 1t, 2a, 2b, 2d, 2l and 2n). Then, a 
total of 1664 molecular descriptors were calculated for each of the selected compound, 
using the E-Dragon software [21,22]. The descriptors were separated in 4 categories: 
molecular properties (43), 1D (322), 2D (578) and 3D (721). This category separation is 
based on how they are calculated by E-Dragon thus providing different information. Then, 
the descriptors correlation with pGI50 values was calculated, for both anti-HCC and 
hepatotoxicity. Only correlation values above 0.80 were considered relevant and are 
presented on table 3. To better discuss the different descriptors with good correlations, they 
are separated in categories and the definition of each relevant descriptor is given on table 4. 
From the molecular properties and 1D categories, only the Hy (hydrophilic factor), the 
nHDon (the number of hydrogen Donors) and nArNH2 (number of amino groups linked to 
aryl group) descriptors provided good correlations with anti-HCC activity. This information 
is in agreement with the SAR analysis made before, and demonstrates that amino groups 
linked to aryl (nArNH2) is a key factor on anti-HCC activity. In fact, the amino group was 
the only substituent used with hydrogen bond donating capability, thus explaining the 
nHDon descriptor correlation and consequently the Hy descriptor. We can assume that 
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probably other functional groups hydrogen bond donors, in the same positions as the amino 
groups, may yield similar or better anti-HCC activities. 
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Table 3 
Correlations (above 0.80) between the calculated molecular descriptors and the pGI50 
values of anti-HCC and hepatotoxicity. 
Sample 
Molecular Properties 1D 2D 3D 
Descriptors Corr. Descriptors Corr. Descriptors Corr. 
Anti-HCC 
activity 
(10 compounds) 
Hy 0.84 nArNH2 nHDon 
0.8385 
0.8385 - 
G1u  
G2s 
G1m 
G1e 
0.9695 
0.9339 
0.9095 
0.9095 
Hepatotoxicity 
(16 compounds) - - 
N-075 
nPyrimidines 
nHAcc 
0.8600 
0.8228 
0.8216 
- 
R8u+ 
R8e+ 
R6m 
R6v+ 
 0.8381 
 0.8216 
 0.8100 
 0.8032 
 
Table 4 
Symbols for the descriptors used and their definition. 
Category Symbols Descriptor definition 
Molecular 
Properties 
Hy hydrophilic factor 
AlogP Ghose-Crippen octanol-water partition coefficients (logP) 
1D 
nArNH2 number of primary amines (aromatic) 
nHDon number of donor atoms for H-bonds (N and O) 
N-075 R--N--Re / R--N--X 
nPyrimidines number of Pyrimidines 
nHAcc number of acceptor atoms for H-bonds (N, O, F) 
3D 
GETWAY 
 
G1u 1st component symmetry directional WHIM index / unweighted 
G2s 2st component symmetry directional WHIM index / weighted by atomic 
electrotopological states 
G1m 1st component symmetry directional WHIM index / weighted by atomic 
masses 
G1e 1st component symmetry directional WHIM index / weighted by atomic 
Sanderson electronegativities 
R8u+ R maximal autocorrelation of lag 8 / unweighted 
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R8e+ R maximal autocorrelation of lag 8 / weighted by atomic Sanderson 
electronegativities 
R6m R autocorrelation of lag 6 / weighted by atomic masses 
R6v+ R maximal autocorrelation of lag 6 / weighted by atomic van der Waals 
volumes 
 
However the best correlations with anti-HCC activity were obtained using 3D descriptors, 
while no correlation was obtained with 2D descriptors. The software E-Dragon calculates 
several categories of 3D descriptors based on the algorithms used and calculation 
approaches [23]. The 3D descriptors of the WHIM (weighted holistic invariant molecular) 
category were the only 3D correlated descriptors, with values well above 0.90. WHIM 
descriptors are built in such a way as to capture the relevant molecular 3-D information 
regarding molecular size, shape, symmetry, and atom distribution with respect to some 
invariant reference frame. Thus they usually perform better when the spatial configuration 
and the stereo-chemistry of the compounds are determinant factors to the biological activity 
studied, in this case the anti-HCC [23,24]. Therefore, the main mechanism of action of the 
methyl 3-aminothieno[3,2-b]pyridine-2-carboxylates derivatives is probably as  modulators 
of protein targets involved in signaling pathways that have been associated with HCC [25]. 
As more methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylates derivatives will be 
synthesized, we expect to translate this information into predictive QSAR models, probably 
using the WHIM descriptors. 
When we correlate descriptors with hepatotoxicity, we observe that only 1D and 3D 
descriptors have correlation values above 0.80. The best correlated 1D descriptor is N-075 
(number of Nitrogen atoms linked though conjugated bond to two atoms), and, on this 
condition, nitrogens act as Hydrogen Bond Acceptors thus explaining the other correlated 
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descriptor nHAcc (number of hydrogen bond acceptors) observed. Furthermore, 
hepatotoxicity also correlates well with the nPyrimidines (number of Pyrimidines) 
descriptor, thus confirming the SAR analysis made before that pyrimidine groups are 
undesirable moieties on the methyl 3-aminothieno[3,2-b]pyridine-2-carboxylates 
derivatives. Taken together, these informations confirm that substituted heteroaryl moieties, 
with hydrogen bond acceptor atoms, are undesirable characteristics for the methyl 3-
aminothieno[3,2-b]pyridine-2-carboxylates derivatives, as they confer greater 
hepatotoxicity.  
The 3D descriptors that better correlate with hepatotoxicity belong to the GETAWAY 
(GEometry, Topology, and Atom-Weights AssemblY) category. These descriptors are 
based on matching 3D-molecular geometry with chemical information, and are based on 
well-known accepted algorithms and formula, possessing a track record of good predictive 
power in biological property modeling [23,26]. The fact that hepatotoxicity correlates with 
3D descriptors from a different category, when compared to the anti-HCC activity, is also 
an indication that the mechanism of action in both biological activities is probably different. 
Although the PLP1 cell culture used is not a “pure” hepatocytes culture, biotransformation 
of the methyl 3-aminothieno[3,2-b]pyridine-2-carboxylates derivatives is also probably a 
factor in the observed hepatotoxicity, as the metabolites produced are maybe the cause of 
toxicity. This information is impossible to derive from the 3D descriptors and the 
hepatotoxicity mechanism will become more apparent as more studies, specially in vivo 
assays, are performed. 
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3. Conclusions 
In this study, a total of thirty-two methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate 
derivatives, belonging to two different series: methyl 3-amino-6-(hetero)arylthieno[3,2-
b]pyridine-2-carboxylates derivatives (1a-1t) and methyl 3-amino-6-
[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates derivatives (2a-2n) were 
evaluated for the in vitro anti-HCC activity and hepatotoxicity using HepG2 and PLP1 cell 
lines, respectively. Compounds 1d, 2f and 2g revealed promising results, with strong anti-
HCC activity and low hepatotoxicity. In common they have an amino substituted benzene 
moiety at the 6-position of the thieno[3,2-b]pyridine scaffold. Compound 2f is the most 
potent anti-HCC compound (GI50 values of 1.2 µM compared to 2.9 µM of ellipticine) with 
no observed hepatotoxicity (GI50>125 µM, compared to 3.3 µM of ellipticine). On the other 
hand, the presence of several moieties linked to the  6-position  contributed to 
hepatotoxicity including: methoxy substituted benzene moieties (1b, 2d), pyridine moieties 
(1i, 2m), thiophene moieties (1n, 2l) and notably quinoline moieties (1p, 1q, 1r). These 
compounds are not suitable scaffolds for pursuing the synthesis of compounds with more 
efficient anti-HCC activity and low hepatotoxicity. 
HepG2 cell cycle analysis of compound 2f indicates that the mechanism of action of this 
compound is related with G2/M cell cycle arrest. 
 QSAR studies were also performed, and revealed that the 3D-WHIM descriptors were the 
ones that correlated best with anti-HCC activity, while the 3D-GETWAY descriptors 
correlated best with hepatotoxicity. All together, these findings indicate that the studied 
compounds promote anti-HCC and hepatotoxicity through different mechanisms, probably 
also as modulators of protein kinase targets such as growth factor receptors involved in 
different signaling pathways. These studies have also confirmed the importance of the 
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presence of the amino groups, and of hydrogen bond donors in general. In conclusion, 
several compounds present potent in vitro anti-HCC activity using HepG2 cells with no 
hepatotoxicity,. Furthermore, they might be used as scaffolds for synthesis of even more 
potent compounds.   
 
4. Experimental  
4.1. Tested compounds 
Thirty-two methyl 3-aminothieno[3,2-b]pyridine-2-carboxylates derivatives belonging to 
two different series: the methyl 3-amino-6-(heteroaryl)thieno[3,2-b]pyridine-2-carboxylates 
derivatives (1a-1t) and the methyl 3-amino-6-[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-
carboxylates derivatives (2a-2n), were prepared. The synthesis was performed by our group 
as previously described [16-18]. Stock solutions were prepared in DMSO and kept at -80 
ºC. Appropriate fourfold serial dilutions were freshly prepared in 10% (v/v) DMSO to 
allow for final well concentrations on the cell assays of: 125.0, 31.2, 7.8, 1.95, 0.49, 0.12 
and 0.03 µM. The effect of the vehicle solvent (DMSO) on the growth of the cell lines was 
evaluated by exposing untreated control cells to the maximum concentration of DMSO 
used in the assay (0.25 %). No influence was found. 
 
4.2. Reagents 
Dulbecco’s modified Eagle’s medium, hank’s balanced salt solution (HBSS), fetal bovine 
serum (FBS), L-glutamine, trypsin-EDTA, penincillin/streptomycin solution (100 U/mL 
and 100 mg/mL, respectively), all purchased from Gibco Invitrogen LifeScience 
(California, USA). Sulforhodamine B, trypan blue, acetic acid, dimethyl sulfoxide 
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(DMSO), ellipticine, ethylene diamine tetraacetic acid (EDTA), Trichloroacetic acid (TCA) 
and Tris were purchased from SigmaChemical Co. (Saint Louis, USA). 
 
4.3. Cell Lines 
In this work, two cell lines were used, the human hepatocellular liver carcinoma cell line 
HepG2 and a porcine liver primary cell culture (PLP1). The PLP1 cell culture was prepared 
from a freshly harvested porcine liver obtained from a local slaughter house. Briefly, the 
liver tissues were rinsed in hank’s balanced salt solution containing 100 U/mL penicillin, 
100 ug/mL streptomycin (Gibco Invitrogen Life Technologies) and divided into 1×1 mm3 
explants. Some of these explants were placed in 25 cm2 tissue flasks in DMEM medium 
supplemented with 10% fetal bovine serum, 2 mM nonessential amino acids and 100 U/mL 
penicillin, 100 mg/mL streptomycin. Both cell lines were incubated at 37°C with a 
humidified atmosphere containing 5% CO2. The medium was changed every two days. 
Cultivation of the cells was continued with direct monitoring every two to three days using 
a phase contrast microscope.  
Before confluence was reached, both HepG2 and PLP1 cells were subcultured and plated in 
96-well plates at a density of 2.5×104 cells/well, and cultivated in DMEM medium with 
10% FBS, 100 U/mL penicillin and 100 mg/mL streptomycin.  
 
4.4. Cell Growth Inhibition Assay using HepG2 and PLP1 cells. 
The tested compounds in vitro effect on HepG2 and PLP1 cell growth was studied, using 
the sulforhodamine B (SRB) colorimetric assay [27], according to Vishai et al., with some 
adaptations [28]. Briefly, exponentially growing cells were seeded in 96-well plates and 
 22 
exposed to six serial dilutions of each tested compound, with final concentrations of 
125.00, 31.25, 7.81, 1.95, 0.49 and 0.12 µM. After 72 h of exposure, cells were fixed by 
adding cold 50% (wt/vol) trichloroacetic acid (TCA, 25 µL) and incubated for 60 min at 4 
ºC. Plates were then washed with deionized water and dried; SRB solution (0.1% wt/vol in 
1% acetic acid, 50 µL) was then added to each plate well and incubated for 30 min at room 
temperature. Unbound SRB was removed by washing with 1% acetic acid. Plates were air-
dried and bound stain was solubilized with 100 µL of a 100 mM Tris base solution. Optical 
densities were read on an automated spectrophotometer plate reader at a single wavelength 
of 540 nm (Biotek Elx800). Dose-response curves were obtained for each tested compound 
and cell line, and the GI50 value, corresponding to the concentration of the compounds that 
inhibited 50 % of the net cell growth, was calculated as described elsewhere [28]. The GI50 
values are expressed as mean ± SEM of three independent experiments.  
 
4.5 Analysis of cell cycle profile 
HepG2 cells were seeded in 6-well plates (8x 104 cells/well) and treated 24h later with 4.1 
µM of compound 2f. Blank cells (treated with medium only) or Control cells (treated with 
the compound’s vehicle, DMSO) were also included. Following 72 h treatment, cells were 
fixed overnight in ice-cold 70% ethanol and re-suspended in PBS containing 0.1 mg/mL 
RNase A and 5 µg/mL propidium iodide. The cellular DNA content was analysed by flow 
cytometry using an Epics XL-MCL Coulter Flow cytometer (Brea, CA, USA) plotting at 
least 5 000 events per sample, as previously described [17, 29]. The % of cells in G0/G1, S 
and G2/M phases of the cell cycle and the % of cells in the sub-G1 peak were determined 
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using the FlowJo 7.2 software (Tree Star, Inc., Ashland, OR, USA) after cell debris and 
aggregates exclusion. 
4.6. 3D structure preparation and molecular descriptors calculation 
The 2D chemical structures of the tested compounds were drawn using the Symyx/Draw 
software [30]. Then, 2D to 3D structure conversion and geometry optimization calculations 
were performed for each compound, using the AMMP force field sp4 [31], developed on 
the basis of the UFF potential set [32] and available via the VegaZZ software [33]. Finally 
the 3D structure of each compound was recorded in mol2 file format also using the VegaZZ 
software. The E-Dragon computer software was then employed to calculate the molecular 
descriptors totaling 1664 descriptors belonging to different categories: molecular 
properties, OD, 1D, 2D and 3D [20,23]. pGI50 values used for molecular modeling were 
calculated according to the equation: pGI50 = log 1/GI50. Correlations were calculated using 
the OpenOffice.org spreadsheet software, version 3.2. 
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